Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Abbott Laboratories
(NY:
ABT
)
105.52
-0.09 (-0.09%)
Streaming Delayed Price
Updated: 1:45 PM EDT, Jul 31, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Abbott Laboratories
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
57
58
Next >
Abbott Undercuts Its 200-Day Line And A Flat Base Despite Its 'Solid' Quarterly Report
↗
April 17, 2024
Abbott Laboratories came in Wednesday with a "solid" first-quarter report that included a guidance raise, but shares fell.
Via
Investor's Business Daily
Abbott Labs Q1 Revenue Jumps On Strong Medical Devices Sales, Company Boosts Annual Guidance
↗
April 17, 2024
Abbott Laboratories surpasses expectations with Q1 sales hitting $9.96B, a 10.8% rise driven by robust performance in Medical Devices, Established Pharmaceuticals, Nutrition, and Diagnostics. CEO...
Via
Benzinga
Wall Street Poised To Rebound From Slump As Earnings Optimism Grows: Analyst Eyes This S&P 500 Level As Attractive Entry Point
↗
April 17, 2024
U.S. stocks are priming for a firmer start on Wednesday, potentially striving to inflect higher from the weakness seen so far in April. As some bullish market watchers pointed out there could be an...
Via
Benzinga
Topics
Stocks
Earnings Scheduled For April 17, 2024
↗
April 17, 2024
Companies Reporting Before The Bell • ASML Holding (NASDAQ:ASML) is projected to report quarterly earnings at $3.43 per share on revenue of $6.13 billion.
Via
Benzinga
Abbott Laboratories Dividend Stock Analysis
↗
April 12, 2024
Abbott Laboratories discovers, develops, manufactures, and sells healthcare products. Its products include branded generic pharmaceuticals manufactured internationally, marketed, and sold outside the...
Via
Talk Markets
Investor Optimism Decreases; Dow Ends 6-Session Losing Streak
↗
April 17, 2024
The CNN Money Fear and Greed index showed a decline in the overall market sentiment, with the index remaining in the "Fear" zone on Tuesday. U.S. stocks closed mixed on Tuesday amid increased...
Via
Benzinga
Topics
Stocks
Abbott Laboratories, U.S. Bancorp And 3 Stocks To Watch Heading Into Wednesday
↗
April 17, 2024
With U.S. stock futures trading higher this morning on Wednesday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
Johnson & Johnson is as Cheap as it’s Going to Get
April 16, 2024
Johnson & Johnson raised its dividend for the 62nd consecutive year and has the power to continue raising the annual payout indefinitely.
Via
MarketBeat
Healthcare Stocks Are Lagging With Big Earnings Weeks Ahead
↗
April 16, 2024
Healthcare stocks disappointed again last week with the XLV down over 3% and up only 1.65 % YTD, in a continued downtrend since March 28.
Via
Talk Markets
Abbott Laboratories Unusual Options Activity
↗
April 11, 2024
Via
Benzinga
Analyst Ratings For Abbott Laboratories
↗
April 03, 2024
Via
Benzinga
How Is The Market Feeling About Abbott Laboratories?
↗
March 28, 2024
Via
Benzinga
3 Buy Rated Stocks To Consider As Earnings Approach
↗
April 13, 2024
With the Q1 earnings season underway, there will be a microscope on companies that can continue to show improvements in their outlook amid an uptick in inflation.
Via
Talk Markets
Jim Cramer Calls Cummins 'Terrific,' Recommends Selling This Chinese Auto Manufacturer
↗
April 12, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes New Fortress Energy Inc.
Via
Benzinga
Why Wall Street Got Even More Excited About The Glucose Monitor — And How Dexcom, Abbott Labs Stand To Benefit
↗
April 12, 2024
Continuous glucose monitors have spiked in popularity since the advent of weight-loss drugs. Is chronic disease at its end?
Via
Investor's Business Daily
Got $200? 2 Healthcare Stocks to Buy and Hold Forever.
↗
April 11, 2024
These companies provide stability, reliability, and passive income.
Via
The Motley Fool
7 Healthcare Stocks to Keep Your Portfolio in Tip-Top Shape
↗
April 10, 2024
Although the market may be grumbling over certain issues, concerned investors can trust these healthcare stocks to deliver the goods.
Via
InvestorPlace
Performance Comparison: Abbott Laboratories And Competitors In Health Care Equipment & Supplies Industry
↗
March 27, 2024
Via
Benzinga
Jim Cramer Was Upset At This Hostile Takeover, But 'They Fixed The Situation. Stock's Been A Horse'
↗
April 09, 2024
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he prefers Abbott Laboratories (NYSE: ABT) over
Via
Benzinga
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
↗
April 09, 2024
Income-seeking investors can look forward to steady payout raises from these pharma stocks.
Via
The Motley Fool
3 Top Dividend Stocks to Buy in April 2024
↗
April 06, 2024
Each of these high-quality stocks looks like a buy.
Via
The Motley Fool
Top Analyst Reports For T-Mobile US, Abbott Laboratories & Palo Alto Networks
↗
April 06, 2024
Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), Abbott Laboratories (ABT) and Palo Alto Networks, Inc. (PANW).
Via
Talk Markets
FDA Approves Abbott's Heart Valve Repair Device For Patients At Risk Of Complications/Death During Open-Heart Surgeries
↗
April 02, 2024
FDA approves Abbott Laboratories' TriClip TEER system for treating tricuspid regurgitation. Clip technology offers non-invasive repair, fast recovery, and significant improvement in quality of life....
Via
Benzinga
DexCom Stock Gains from GLP-1 Diabetic Users
April 02, 2024
DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People
Via
MarketBeat
Russell 2000 Index Best And Worst Performing Stocks Of 2024
↗
April 02, 2024
The Russell 2000 index continued to underperform the Dow Jones and Nasdaq 100 indices in the first quarter of 2024.
Via
Talk Markets
Topics
Stocks
3 Strong Buy Healthcare Stocks to Add to Your Q2 Must-Watch List
↗
March 29, 2024
In an aging world, strong buy healthcare stocks like UNH, ABT, and MRK shine with dividends, innovation, and market growth.
Via
InvestorPlace
Winning Over Wall Street: 3 Stocks Earning Overwhelming Analyst Approval
↗
March 26, 2024
Discover the investment potential of three stocks with analyst approval for their robust financials and strategic market positions.
Via
InvestorPlace
More Than 86% of Analysts Who Cover These 3 Stocks Rate Them a ‘Buy’
↗
March 25, 2024
Investors should take notice of these stocks with high analyst ratings. It's time to load up your portfolio.
Via
InvestorPlace
Want Decades of Passive Income? 2 Stocks to Buy Now.
↗
March 22, 2024
There aren't many guarantees in the equity market, but the dividend payouts of Johnson & Johnson and Abbott Laboratories may be as close as it gets to a sure thing.
Via
The Motley Fool
3 Stocks to Buy Right Now for the Coming Recession
↗
March 21, 2024
With numerous economic indicators souring, these three stocks to buy for a recession will protect your portfolio's downside.
Via
InvestorPlace
Topics
Economy
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
57
58
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.